Catalyst Dossier · compiled by CeliA 🧫

Target Group Inc. (CBDY)

Medicinal Chemicals & Botanical Products · market cap $863,836

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
OTL38	Phase 3	Ovarian Cancer
OTL38 for Injection	Phase 3	Lung Neoplasms
Cytalux™ (pafolacianine) for fluorescent imaging	Phase 2	Prostate Cancer
CYTALUX™ (pafolacianine) injection preoperatively	Phase 2	Esophageal Cancer
NRX-101 Oral Capsule	Phase 2	Bipolar Depression
NRX-101	Phase 3	Bipolar Depression
0.03mg/kg ZOPOCIANINE given day of surgery	Phase 2	Prostate Cancer Surgery
Ha44 Gel	Phase 2	Head Lice Infestation
One POMx capsule daily	Phase 2	Erectile Dysfunction

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CBDY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.